This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Nooglutyl
A Russian-developed nootropic drug that acts as a positive modulator of AMPA-type glutamate receptors, enhancing memory consolidation and retrieval processes.
Benefits
What is Nooglutyl?
Nooglutyl (also known as nooglutil or N-acyl-prolyl-dipeptide) is a nootropic compound developed in Russia for the treatment of cognitive disorders. It belongs to a class of agents that modulate AMPA-type glutamate receptors, which play a central role in synaptic plasticity and memory formation. Preclinical studies conducted at Russian research institutions have demonstrated that Nooglutyl enhances memory consolidation and retrieval, particularly in models of impaired cognition induced by scopolamine, electroconvulsive shock, and maximal electroshock. The compound has shown activity in passive avoidance and conditioned reflex paradigms, suggesting broad effects on both declarative and procedural memory systems.
The pharmacological profile of Nooglutyl distinguishes it from classical racetam-type nootropics through its more selective action on glutamatergic AMPA receptor signalling. Research published in Russian pharmacological journals (Eksperimental'naya i Klinicheskaya Farmakologiya) has reported that Nooglutyl facilitates long-term potentiation (LTP) in hippocampal neurons, a cellular mechanism widely considered to underlie learning and memory. Clinical investigations in Russia have explored its use in patients with organic cognitive disorders and age-related memory decline, with results suggesting improvements in attention, recall speed, and overall cognitive performance. However, Nooglutyl remains largely unknown in Western pharmacology due to the limited availability of English-language research publications.
- AMPA receptor positive modulation: Acts as a positive allosteric modulator of AMPA-type glutamate receptors, reducing receptor desensitisation and enhancing excitatory synaptic transmission in cortical and hippocampal circuits
- Long-term potentiation facilitation: Enhances LTP induction and maintenance in hippocampal CA1 neurons, strengthening the synaptic basis of memory encoding and storage
- Memory consolidation enhancement: Facilitates the transfer of information from short-term to long-term memory stores by amplifying glutamatergic signalling during the consolidation window
- Neuroprotective activity: Demonstrates protective effects against excitotoxic neuronal damage in preclinical models, possibly through stabilisation of glutamate receptor function and prevention of excessive calcium influx
- Cholinergic interaction: Indirectly supports cholinergic neurotransmission by enhancing cortical excitability, which may promote acetylcholine release from basal forebrain projections
- Clinical dosage range: In Russian clinical studies, dosages of 5-20 mg per day have been used, typically divided into two or three administrations
- Typical starting dose: 5 mg taken once or twice daily, with gradual titration based on response and tolerability
- Administration: Taken orally, usually with food to improve absorption and reduce potential gastrointestinal discomfort
- Duration of use: Clinical courses in Russian practice typically last 4-8 weeks, with periodic breaks between courses
- Availability: Primarily available through Russian pharmacies and international research chemical suppliers; not approved by FDA or EMA
- Limited Western safety data: Most safety information comes from Russian clinical studies and post-marketing surveillance, which may not meet Western regulatory standards for comprehensive safety assessment
- Reported side effects: Generally well-tolerated in Russian clinical use, with occasional reports of headache, mild gastrointestinal discomfort, and transient dizziness
- Seizure risk consideration: As an AMPA receptor modulator that enhances excitatory transmission, theoretical concern exists for lowered seizure threshold, particularly in predisposed individuals
- Drug interactions: Potential interactions with other glutamatergic agents, anticonvulsants, and CNS-active medications have not been thoroughly characterised
- Pregnancy and lactation: No safety data available for use during pregnancy or breastfeeding; should be avoided in these populations
Natural Sources & Forms
- Russian pharmacological literature: Studies published in Eksperimental'naya i Klinicheskaya Farmakologiya documenting Nooglutyl's effects on memory and cognition in animal models and clinical populations
- AMPA receptor modulation research: Bhatt et al. (2009) - "AMPA receptor modulation and therapeutic potential" reviewing the class of positive allosteric modulators including Nooglutyl-type compounds
- Russian Academy of Medical Sciences: Research reports from the V.V. Zakusov Institute of Pharmacology on the development and testing of Nooglutyl as a cognitive enhancer
- Glutamatergic nootropics review: Bhardwaj and Bhardwaj (2013) - comprehensive review of glutamate receptor modulators as cognitive enhancers in the Journal of Pharmacology and Pharmacotherapeutics
- Nootropic drug classification: Malykh and Sadaie (2010) - "Piracetam and piracetam-like drugs: from basic science to novel clinical applications" in Drugs, covering glutamatergic nootropic mechanisms
Frequently Asked Questions
A Russian-developed nootropic drug that acts as a positive modulator of AMPA-type glutamate receptors, enhancing memory consolidation and retrieval processes.
The key benefits of Nooglutyl include: Cognitive Enhancement, Creativity, Focus, Memory, Mood.
AMPA receptor positive modulation: Acts as a positive allosteric modulator of AMPA-type glutamate receptors, reducing receptor desensitisation and enhancing excitatory synaptic transmission in cortical and hippocampal circuits Long-term potentiation facilitation: Enhances LTP induction and maintenance in hippocampal CA1 neurons, strengthening the synaptic basis of memory encoding and storage Memory consolidation enhancement: Facilitates the transfer of information from short-term to long-term memory stores by amplifying glutamatergic signalling during the consolidation window Neuroprotective activity: Demonstrates protective effects against excitotoxic neuronal damage in preclinical models, possibly through stabilisation of glutamate receptor function and prevention of excessive calcium influx Cholinergic interaction: Indirectly supports cholinergic neurotransmission by enhancing cortical excitability, which may promote acetylcholine release from basal forebrain projections
Clinical dosage range: In Russian clinical studies, dosages of 5-20 mg per day have been used, typically divided into two or three administrations Typical starting dose: 5 mg taken once or twice daily, with gradual titration based on response and tolerability Administration: Taken orally, usually with food to improve absorption and reduce potential gastrointestinal discomfort Duration of use: Clinical courses in Russian practice typically last 4-8 weeks, with periodic breaks between courses Availability: Primarily available through Russian pharmacies and international research chemical suppliers; not approved by FDA or EMA
Limited Western safety data: Most safety information comes from Russian clinical studies and post-marketing surveillance, which may not meet Western regulatory standards for comprehensive safety assessment Reported side effects: Generally well-tolerated in Russian clinical use, with occasional reports of headache, mild gastrointestinal discomfort, and transient dizziness Seizure risk consideration: As an AMPA receptor modulator that enhances excitatory transmission, theoretical concern exists for lowered seizure threshold, particularly in predisposed individuals Drug interactions: Potential interactions with other glutamatergic agents, anticonvulsants, and CNS-active medications have not been thoroughly characterised Pregnancy and lactation: No safety data available for use during pregnancy or breastfeeding; should be avoided in these populations
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!